UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.307

Sortiert nach

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Annals of oncology, 2015-01, Vol.26 (1), p.161-166

2015

Link zum Volltext

Verfügbarkeit prüfen

Nanoparticle formation in a chemical storage room as a new incidental nanoaerosol source at a nanomaterial workplace

Journal of hazardous materials, 2015-11, Vol.298, p.36-45

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of particle loading on the collection performance of an electret cabin air filter for submicron aerosols

Journal of aerosol science, 2003-11, Vol.34 (11), p.1493-1504

2003

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Annals of oncology, 2021-03, Vol.32 (3), p.368-374

2021

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Multicenter Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment of Recurrent or Metastatic NAsopharyngeal Cancer (KCSG HN07-01)

Annals of oncology, 2012-10, Vol.23, p.xi156

Ji, J.H.

2012

Link zum Volltext

Verfügbarkeit prüfen

Improvement of gain and noise figure in double-pass L-band EDFA by incorporating a fiber Bragg grating

IEEE photonics technology letters, 2004-04, Vol.16 (4), p.1005-1007

2004

Link zum Volltext
IEEE_Xplore

A Simple and Automated VMAT Treatment Planning for Hippocampal Avoidance Whole Brain Radiotherapy

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e335-e335

2020

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

ESMO open, 2022-04, Vol.7 (2), p.100408-100408, Article 100408

2022

Link zum Volltext

Verfügbarkeit prüfen

Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events

Annals of oncology, 2019-11, Vol.30, p.ix143

2019

Link zum Volltext

Verfügbarkeit prüfen

Degradability comparison of poly(butylene adipate terephthalate) and its composites filled with starch and calcium carbonate in different aquatic environments

Journal of applied polymer science, 2019-01, Vol.136 (2), p.n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Analysis of residual thermal stress for AlN crystal growth by PVT

Vacuum, 2023-08, Vol.214, p.112237, Article 112237

2023

Link zum Volltext

Verfügbarkeit prüfen

422P A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Link zum Volltext

Verfügbarkeit prüfen

422P A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study

Annals of oncology, 2016-12, Vol.27, p.ix132-ix132

2016

Link zum Volltext

Verfügbarkeit prüfen

Low noise-figure gain-clamped L-band double-pass erbium-doped fiber ring lasing amplifier with an interleaver

Journal of lightwave technology, 2005-03, Vol.23 (3), p.1375-1379

2005

Link zum Volltext
IEEE_Xplore

1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

Annals of oncology, 2022-09, Vol.33, p.S1245-S1246

2022

Link zum Volltext

Verfügbarkeit prüfen

141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

Annals of oncology, 2022-04, Vol.33, p.S97-S98

2022

Link zum Volltext

Verfügbarkeit prüfen

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Annals of oncology, 2021-09, Vol.32, p.S1338-S1338

2021

Link zum Volltext

Verfügbarkeit prüfen

379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Annals of oncology, 2020-11, Vol.31, p.S1388-S1389

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Annals of oncology, 2020-09, Vol.31, p.S1212-S1213

2020

Link zum Volltext

Verfügbarkeit prüfen

Performance evaluations of hybrid modulation with different optical labels over PDQ in high bit-rate OLS network systems

Optics express, 2016-11, Vol.24 (23), p.26228-26240

2016

Link zum Volltext

Verfügbarkeit prüfen

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Annals of oncology, 2019-12, Vol.30, p.xi66

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Annals of oncology, 2019-10, Vol.30, p.v928-v929

2019

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Annals of oncology, 2019-10, Vol.30, p.v928-v929

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Annals of oncology, 2019-11, Vol.30, p.ix197-ix198

2019

Link zum Volltext

Verfügbarkeit prüfen

Natural History of Untreated Patients Who Had Metastatic Biliary Tract Cancer (Btc) with Good Performance Status (Ps)

Annals of oncology, 2014-09, Vol.25, p.iv246

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.307

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.178)
Mit Volltextzugriff
(1.194)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(980)
Life Sciences & Biomedicine
(755)
Biological And Medical Sciences
(206)
Animals
(192)
Physical Sciences
(184)
Humans
(171)
생물학
(162)
Food Science & Technology
(158)
Fundamental And Applied Biological Sciences. Psychology
(154)
Technology
(149)
Biochemistry & Molecular Biology
(148)
Biotechnology
(127)
Chemistry
(126)
Biotechnology & Applied Microbiology
(118)
Male
(112)
Physics
(112)
Microbiology
(109)
Exact Sciences And Technology
(100)
Cell Biology
(97)
Engineering
(88)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Nanoparticle formation in a chemical storage room as a new incidental nanoaerosol source at a nanomaterial workplace

Effect of particle loading on the collection performance of an electret cabin air filter for submicron aerosols

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

A Prospective Multicenter Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment of Recurrent or Metastatic NAsopharyngeal Cancer (KCSG HN07-01)

Improvement of gain and noise figure in double-pass L-band EDFA by incorporating a fiber Bragg grating

A Simple and Automated VMAT Treatment Planning for Hippocampal Avoidance Whole Brain Radiotherapy

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events

Degradability comparison of poly(butylene adipate terephthalate) and its composites filled with starch and calcium carbonate in different aquatic environments

Analysis of residual thermal stress for AlN crystal growth by PVT

422P A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study

422P A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study

Low noise-figure gain-clamped L-band double-pass erbium-doped fiber ring lasing amplifier with an interleaver

1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Performance evaluations of hybrid modulation with different optical labels over PDQ in high bit-rate OLS network systems

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Natural History of Untreated Patients Who Had Metastatic Biliary Tract Cancer (Btc) with Good Performance Status (Ps)

Suchergebnisse filtern